Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00312650 · ClinicalTrials.gov registry record · Phase 2
Doxil and Gemcitabine in Recurrent Ovarian Cancer
A Phase 2 study, sponsored by Women and Infants Hospital of Rhode Island.
- Terminated
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT00312650: Clinical Trial Phase 2 study, sponsored by Women and Infants Hospital of Rhode Island.
NCT00312650 is a Phase 2 study that was terminated before completion, run by Women and Infants Hospital of Rhode Island. The registered enrollment target is 24 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (82% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00312650, a Phase 2 study, was terminated before completion, sponsored by Women and Infants Hospital of Rhode Island.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
Standard treatment for recurrent ovarian cancer is chemotherapy with one or more drugs. One of these drugs, Doxil, can cause skin toxicity at the standard dosages. This study investigates using a lower dose given more frequently in combination with a second drug Gemcitabine.
Interventions
- DRUG liposomal doxorubicin and gemcitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2006-04 |
| Est. Completion | 2006-05 |
| Phase | Phase 2 |
Why NCT00312650 stopped before completion
NCT00312650 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (82% lower).
The record links to 0 conditions, and to 1 intervention - of which liposomal doxorubicin and gemcitabine is the first listed.
NCT00312650 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00312650 about?
NCT00312650 is a clinical study titled "Doxil and Gemcitabine in Recurrent Ovarian Cancer". Standard treatment for recurrent ovarian cancer is chemotherapy with one or more drugs. One of these drugs, Doxil, can cause skin toxicity at the standard dosages. This study investigates using a lower dose given more frequently in combination with a second drug Gemcitabine.
What is the current status of trial NCT00312650?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2006-04. Estimated completion is 2006-05.
What interventions are being tested in trial NCT00312650?
The interventions under investigation include: liposomal doxorubicin and gemcitabine (DRUG).
Who is sponsoring clinical trial NCT00312650?
This trial is sponsored by Women and Infants Hospital of Rhode Island, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00312650's enrollment target sits among peer trials
24 1756th of 2000 higher than 217 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia